Table 1. Baseline characteristics stratified by the protocol applied.
| Characteristics | R-MPL (N=69) | R-MP (N=38) | All (N=107) |
|---|---|---|---|
| Median age (range), years | 73 (66–85) | 73 (66–85) | 73 (66–85) |
| Female | 34 (49.3) | 16 (42.1) | 50 (46.7) |
| Karnofsky performance statusa | |||
| Median (range) | 70 (30–100) | 60 (30–100) | 70 (30–100) |
| ⩾70% | 32 (56.1) | 17 (47.2) | 49 (52.7) |
| Lymphoma lesionsb | |||
| Single | 28 (41.2) | 13 (34.2) | 41 (38.7) |
| Multiple | 40 (58.8) | 25 (65.8) | 65 (61.3) |
| Lymphoma location | |||
| Infratentorial | 11 (16.2) | 10 (26.3) | 21 (19.8) |
| Supratentorial | 50 (73.5) | 20 (52.6) | 70 (66.0) |
| Both | 7 (10.3) | 8 (21.1) | 15 (14.2) |
| Serum lactate dehydrogenasec | |||
| Elevated | 30 (44.8) | 17 (45.9) | 47 (45.2) |
| Normal | 37 (55.2) | 20 (54.1) | 57 (54.8) |
| Ocular involvement | 1 (1.5) | 0 (0) | 1 (0.9) |
| Histology | |||
| DLBCL | 69 (100.0) | 38 (100.0) | 107 (100.0) |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; R-MP, rituximab, methotrexate and procarbazine; R-MPL, rituximab, methotrexate, procarbazine and lomustine.
Numbers are frequencies (proportions) unless specified otherwise.
a
Karnofsky performance status missing in 12 patients.
b
Missing in 1 patient.
c
Missing in 2 patients.